Every Form 4 that Organogenesis Holdings Inc. (ORGO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ORGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ORGO filings page.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow exercised stock options to acquire 958 shares of Class A Common Stock on January 10, 2025 at $1.24 per share. The option was fully vested and, after the transaction, he directly holds 900,682 shares.
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at a price of $2.681 per share on March 9, 2026. Following this transaction, his directly held stake increased to 291,014 shares.
Organogenesis Holdings Inc. director Michael Joseph Driscoll bought 10,000 shares of Class A Common Stock in an open-market purchase. He paid about $2.67 per share, for a total of roughly $26,688. Following this transaction, he directly owns 225,707 shares, making this a relatively small addition to his stake.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported a tax-related share transfer. On this transaction, 700 shares of Class A common stock were disposed of at $3.21 per share to cover tax withholding obligations, leaving him with 275,524 directly held shares.
Organogenesis Holdings Inc. executive Antonio S. Montecalvo reported updated stock transactions related to an equity award. The amended filing corrects the number of Class A Common shares acquired upon vesting of a performance share award and the shares withheld to cover taxes. On February 18, 2026, he was granted 11,330 shares at a price of $0.00 per share and had 3,778 shares withheld at $3.84 per share to satisfy tax obligations. After these adjustments, he directly holds 226,238 Class A Common shares. The amendment states no other changes were made to the original report.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported updated equity compensation activity. On February 18, 2026, he acquired 188,856 shares of Class A common stock as a grant or award at $0.00 per share, and disposed of 91,311 shares at $3.84 per share to cover tax obligations. The amendment corrects the numbers previously reported for the performance share vesting and related tax-withholding, with no other changes to the original Form 4.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow filed an amended insider transaction report. On February 18, 2026, he acquired 48,818 shares of Class A common stock at $0.00 per share through the vesting and settlement of a performance share award, and 11,887 shares were disposed of at $3.84 per share to cover tax obligations. After these adjustments, he directly owns 899,724 shares. The amendment corrects the previously reported share amounts related to this award, with no other changes.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares reported from a performance share award that vested on February 18, 2026 and the related tax withholding. The filing now shows an award acquisition of 49,102 shares at a stated price of $0.00 per share and a tax-withholding disposition of 16,375 shares at $3.84 per share. Following these adjustments, Bilbo directly holds 1,128,312 shares of Class A Common Stock.
Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported amended equity award details. On February 18, 2026, he acquired 44,040 shares of Class A common stock as a grant at no cost, and 14,687 shares were withheld at $3.84 per share to cover tax obligations. This amendment only corrects the share counts previously reported for the award vesting and related tax withholding.
Organogenesis Holdings Inc. executive Robert Cavorsi, Vice President of Strategy, filed an amended insider report updating a prior Form 4. The amendment corrects the number of Class A Common Stock shares acquired upon vesting and settlement of a performance share award and the shares withheld for taxes. On February 18, 2026, he was granted 16,454 shares at $0.00 per share and had 5,487 shares withheld at $3.84 per share to satisfy tax obligations. Following these adjustments, his direct holdings total 276,224 Class A shares. The filing states no other changes were made to the original report.
Organogenesis Holdings Inc. executive Lori Freedman updated her insider holdings following a performance share award. She acquired 43,212 shares of Class A common stock at no cost from the vesting and settlement of a performance share award, and 14,411 shares were withheld to cover related tax obligations. This amended Form 4 corrects the originally reported acquired and tax-withheld share amounts, with no other changes to the prior filing.
Organogenesis Holdings Inc. executive Lori Freedman, Chief Administrative and Legal Officer, reported multiple equity awards. She received a stock option for 115,812 shares at $0 per share, vesting in equal annual installments over four years beginning February 15, 2026. She was also granted 203,125 restricted stock units under the 2018 Equity Incentive Plan, each convertible into one share of Class A common stock, vesting annually over four years from the same date. In addition, 42,780 shares of Class A common stock were issued upon vesting and settlement of a 2025 performance share award. A separate disposition of 14,267 shares at $3.84 per share was reported to cover tax obligations by delivering shares, leaving her with 1,023,355 Class A shares directly owned after these transactions.
Organogenesis Holdings Inc. vice president Robert Cavorsi reported multiple equity awards and a related tax share disposition. He received stock options for 53,452 shares at an exercise price of $0.00 and now holds 53,452 derivative securities. He was also granted 93,750 shares of Class A common stock and a further 16,290 shares, bringing his direct Class A holdings to 276,115 shares after all transactions.
The awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, and options that become exercisable on the same schedule. Some shares were issued from a 2025 performance share award tied to performance milestones. A total of 5,432 shares were withheld and disposed at $3.84 per share to cover tax obligations.
Organogenesis Holdings Inc. reported that Chief Financial Officer Francisco David received equity awards and had shares withheld for taxes. He was granted a stock option for 111,358 shares with no exercise cost shown here, vesting in equal annual installments over four years beginning February 15, 2026. He also received 195,312 restricted stock units, each convertible into one share of Class A common stock as they vest annually over four years starting on the same date. In addition, 43,602 shares of Class A common stock were issued upon vesting of a 2025 performance share award tied to performance milestones, and 14,541 shares were disposed of at $3.84 per share to cover tax obligations. Following these transactions, he directly owned 731,020 Class A shares.
Organogenesis Holdings Inc. reported that Chief Commercial Officer Brian Grow received new equity awards and had shares withheld for taxes. He was granted a stock option for 133,630 shares with no exercise price shown here; the option vests in equal annual installments over four years beginning February 15, 2026.
Grow also acquired 234,375 shares and 48,330 shares of Class A common stock as equity awards, tied to restricted stock units and a performance share award that vest over time based on service and performance. In connection with the vesting of the performance award, 11,768 shares were disposed of at $3.84 per share to satisfy tax withholding obligations, leaving him with 899,355 shares of Class A common stock held directly.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported new equity awards and related tax withholding transactions. He received a stock option covering 120,267 shares of Class A common stock and was granted or issued a total of 259,549 Class A shares through stock awards on February 18, 2026.
The equity awards include restricted stock units that vest in equal annual installments over four years beginning February 15, 2026, as well as shares issued from a 2025 performance share award based on achievement of performance milestones. In a separate transaction, 16,212 shares were disposed of at $3.84 per share to cover tax obligations tied to these awards.
Organogenesis Holdings Inc. reported that President and CEO Gary S. Gillheeney received equity awards and related share settlements. He was granted 890,625 restricted stock units that vest in equal annual installments over four years beginning February 15, 2026. He also received 186,968 shares of Class A common stock upon vesting and settlement of a 2025 performance share award tied to performance milestones. To cover tax obligations, 90,398 shares were disposed of at $3.84 per share. In addition, he was granted stock options for 507,795 shares, which become exercisable in equal annual installments over four years beginning February 15, 2026, bringing his directly held Class A shares to 4,231,112 and option holdings to 507,795.
Organogenesis Holdings Inc. director Michael Joseph Driscoll received an equity grant in the form of restricted stock units (RSUs) covering 48,828 shares of Class A common stock. The award was granted at no cash cost per share and represents a compensation-related acquisition, not an open-market purchase.
Each RSU converts into one share of Class A common stock upon vesting. The RSUs vest in full on February 15, 2027, meaning Driscoll will receive the underlying shares only if the vesting conditions are satisfied. Following this grant, his directly held Class A share balance reported in this filing is 215,707 shares.
Giacomin Jon L reported acquisition or exercise transactions in this Form 4 filing.
Organogenesis Holdings Inc. director Jon L. Giacomin reported receiving an equity grant in the form of restricted stock units (RSUs). The award covers 48,828 RSUs, each representing one share of Class A common stock upon vesting. These RSUs vest in full on February 15, 2027, aligning his compensation with long‑term shareholder value. Following this grant, Giacomin directly owns 241,026 shares of Organogenesis Class A common stock.
Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an equity award of Class A common stock. He acquired 48,828 shares through a grant of restricted stock units (RSUs) at no cash cost, increasing his directly held stake to 286,014 shares after the transaction.
The RSUs were granted under the Organogenesis 2018 Equity Incentive Plan. Each RSU converts into one share of Class A common stock upon vesting, and the entire award is scheduled to vest in full on February 15, 2027, aligning director compensation with the company’s long-term performance.
Organogenesis Holdings Inc. vice president Antonio S. Montecalvo reported multiple equity compensation awards. On February 18, 2026, he received a stock option for 23,162 shares at an exercise price of $0.00 and restricted stock units for 40,625 shares and 11,218 shares of Class A common stock.
The RSUs were granted under the 2018 Equity Incentive Plan and vest in equal annual installments over four years beginning on February 15, 2026. The option also becomes exercisable in equal annual installments over four years beginning on the same date.
In connection with the vesting and settlement of a 2025 performance share award based on achievement of performance milestones, 3,741 Class A shares were disposed of at $3.84 per share to cover tax withholding, leaving Montecalvo with 226,163 Class A shares held directly.
Organogenesis Holdings Inc. director Gilberto Quintero reported an equity award of 48,828 restricted stock units (RSUs) of Class A common stock under the company’s 2018 Equity Incentive Plan. Each RSU converts into one share upon vesting, and the award vests in full on February 15, 2027. Following this grant, Quintero directly holds 239,073 shares of Class A common stock.
Duraibabu Prathyusha reported acquisition or exercise transactions in this Form 4 filing.
Organogenesis Holdings Inc. director Prathyusha Duraibabu reported an equity award of 48,828 restricted stock units (RSUs) of Class A common stock. The RSUs were granted under the company’s 2018 Equity Incentive Plan at a price of $0.00 per unit, reflecting a compensatory grant rather than an open‑market purchase.
Each RSU represents the right to receive one share of Class A common stock upon vesting, and the award vests in full on February 15, 2027. Following this grant, Duraibabu’s directly held Class A common stock (including underlying RSUs as reported) totals 247,047 shares, highlighting an increase in her equity‑based alignment with shareholders.
Organogenesis Holdings Inc. director Garrett Lustig reported an equity award from the company. He acquired 48,828 shares of Class A common stock through a grant of restricted stock units (RSUs) at a price of $0.00 per share, bringing his direct holdings to 125,742 shares.
Each RSU represents the right to receive one share of Organogenesis Class A common stock upon vesting. According to the grant terms, all of these RSUs vest in full on February 15, 2027, aligning Lustig’s compensation with the company’s long-term performance.
Organogenesis Holdings Inc. director Michele Ilene Korfin received an equity grant in the form of restricted stock units (RSUs). The award covers 48,828 shares of Class A common stock at a stated price of $0.00 per share.
Each RSU converts into one share of Class A common stock upon vesting, and the RSUs vest in full on February 15, 2027. After this grant, Korfin’s directly held Class A common stock reported in the filing totals 239,073 shares.
Organogenesis Holdings Inc. Chief Financial Officer Francisco David reported four tax-withholding dispositions of Class A common stock on February 15, 2026, at $3.73 per share. After these transactions related to tax obligations, he directly owned 506,647 Class A shares.
Organogenesis Holdings Inc. Chief Operating Officer Patrick Bilbo reported several insider transactions involving Class A common stock. On February 15, 2026, he disposed of shares in four separate transactions coded “F,” which indicates shares were delivered to cover a tax liability or exercise price.
Across these tax-withholding dispositions, shares were transferred at a reported price of $3.73 per share. After the final transaction, Bilbo continued to directly own 884,648 shares of Class A common stock, reflecting a substantial remaining equity stake in the company.
Organogenesis Holdings Inc. vice president of strategy Robert Cavorsi reported three tax-withholding dispositions of Class A Common Stock tied to equity compensation. On February 15, 2026, he delivered 6,667, 5,549 and 5,442 shares at $3.73 per share to cover tax obligations, and continued to hold a substantial direct stake afterward.
Organogenesis Holdings Inc. reported insider tax-related share dispositions by Chief Administrative and Legal Officer Lori Freedman. On February 15, 2026, she executed four Form 4 code F transactions in Class A common stock, delivering 4,043, 24,428, 12,761 and 13,510 shares at $3.73 per share to cover tax liabilities. Following these non-open-market transactions, she held 791,717 shares directly.
Organogenesis Holdings Inc. President and CEO Gary S. Gillheeney reported several tax-related share dispositions of Class A Common Stock. On February 15, 2026, he delivered an aggregate of 271,406 shares at $3.73 per share to satisfy tax withholding obligations. Following these transactions, he directly owned 3,243,917 Class A Common shares.
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow reported four tax-withholding dispositions of Class A common stock on February 15, 2026. The transactions, coded “F” and priced at $3.73 per share, were used to satisfy tax liabilities and left him with 628,418 shares held directly.
Organogenesis Holdings Inc. vice president of health policy Antonio S. Montecalvo reported four tax-withholding dispositions of Class A Common Stock on February 15, 2026. A total of 18,619 shares were delivered at $3.73 per share to cover tax obligations, leaving him with 178,061 directly owned shares.
Organogenesis Holdings Inc. reported an insider stock transaction by a company director. On 12/16/2025, the director sold 200,000 shares of Class A Common Stock in open-market trades at a weighted-average price of $5.1353 per share, with individual trade prices ranging from $5.10 to $5.24.
After this sale, the director directly beneficially owns 2,565,591 shares of Class A Common Stock. In addition, the director has indirect beneficial ownership through three trusts holding 918,680 shares, 7,928,570 shares, and 335,719 shares of Class A Common Stock, respectively.
Organogenesis Holdings Inc. (ORGO) insider activity: A director and 10% owner reported Form 4 transactions. An affiliated trust purchased 251,001 shares of Class A common stock on 05/14/2025 at a weighted-average price of $3.0878 and 107,494 shares on 05/15/2025 at a weighted-average price of $2.9862. The same trust sold 4,156 shares on 06/09/2025 at a weighted-average price of $3.5003 and 18,620 shares on 06/10/2025 at a weighted-average price of $3.5583.
Following the reported transactions, holdings included 335,719 shares indirectly by the Glenn Nussdorf 10 Year Follow On Trust and 3,065,591 shares held directly. The filing notes that the sales on 06/09/2025 and 06/10/2025 were matchable with a 05/15/2025 purchase under Section 16(b), and the reporting person paid the issuer $13,285.24, comprising $12,971.78 in profit plus $313.46 in interest.